Karolinska University Hospital

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

Retrieved on: 
Montag, April 8, 2024
Karolinska University Hospital, EudraCT, PD, L-DOPA, Patient, IGX, Doctor of Philosophy, MD, TSX, Clinical trial, Pharmaceutical industry

SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial.

Key Points: 
  • SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial.
  • MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD.
  • The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm® or placebo twice daily for 18-months, followed by a 3-month washout period.
  • Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents.

KFSH&RC Welcomes Dr. Björn Zoéga as New Deputy CEO

Retrieved on: 
Dienstag, April 2, 2024
Karolinska University Hospital, Health, Education, Research, RC, Karolinska Institute, Landspítali, KFSH, National University Hospital

RIYADH, Saudi Arabia, April 02, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH&RC) is proud to announce the appointment of Dr. Björn Zoéga as Deputy Chief Executive Officer (CEO), effective 01 April 2024. This strategic move is set to accelerate KFSH&RC's aspiration of becoming a leading healthcare institution on the global stage, leveraging Dr. Zoéga's notable career and proven track record of leadership in top-tier medical institutions.

Key Points: 
  • RIYADH, Saudi Arabia, April 02, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH&RC) is proud to announce the appointment of Dr. Björn Zoéga as Deputy Chief Executive Officer (CEO), effective 01 April 2024.
  • His administration at Karolinska was marked by innovative strategies and excellence in healthcare delivery—all which he is posed to enrich within KFSH&RC.
  • Dr. Zoégabrings decades of healthcare management and clinical expertise to KFSH&RC, having spearheaded operations as CEO of the National University Hospital of Iceland and the Stockholm Spine Center.
  • As Deputy CEO, Dr. Zoéga will serve as chief lead of KFSH&RC’s healthcare delivery and research and innovation groups, following on the hospital’s commitment to integrating global best practices in healthcare and pursuing cutting-edge medical research and technology.

SmartCella obtains approval for GMP manufacturing and quality control testing of cell therapies

Retrieved on: 
Mittwoch, Februar 7, 2024
Neoplasm, Certification, CGMP, ATMP, Research, Good, Karolinska University Hospital, Education minister, Research and development, Good manufacturing practice, GMP, Development, Quality, Vaccine

STOCKHOLM, Feb. 7, 2024 /PRNewswire/ -- SmartCella, through its business unit ProCella, has been approved by the Swedish Medicinal Product Agency for manufacturing and quality control testing of sterile biological medicinal products for cell therapy.

Key Points: 
  • STOCKHOLM, Feb. 7, 2024 /PRNewswire/ -- SmartCella, through its business unit ProCella, has been approved by the Swedish Medicinal Product Agency for manufacturing and quality control testing of sterile biological medicinal products for cell therapy.
  • SmartCella is pleased to announce that ProCella has been granted manufacturing authorization as well as Good Manufacturing Practice (GMP) certification from the Swedish Medicinal Product Agency.
  • Niklas Prager, CEO of SmartCella, continues: "The approval of our GMP facility is a key milestone for SmartCella.
  • This, in combination with a stellar quality control system, makes us unique and we have a competitive advantage for future cell therapy product development.

SmartCella strengthens team by recruiting Dr. Nina Bauer as Chief Business Officer

Retrieved on: 
Mittwoch, Januar 3, 2024
RNA, Master of Business Administration, Master, Karolinska University Hospital, Commercial, AstraZeneca, Research, Viral vector, FDA, Acquisition, Cell, Stony Brook University, Business administration, MBA, Sigma-Aldrich, Doctor of Philosophy, Gene, GMP, University of Oldenburg, University, Business development, Neoplasm, Cancer, Growth, Patient, Publication, Head, Therapy, Management

STOCKHOLM, Jan. 3, 2024 /PRNewswire/ -- SmartCella Holding AB today announces that Dr. Nina Bauer, MBA, has been appointed Chief Business Officer and Head of Smartwise.

Key Points: 
  • STOCKHOLM, Jan. 3, 2024 /PRNewswire/ -- SmartCella Holding AB today announces that Dr. Nina Bauer, MBA, has been appointed Chief Business Officer and Head of Smartwise.
  • She will be a member of the SmartCella Exceutive Management Team, and based in Boston (MA, USA).
  • With the strategic recruitment of Nina Bauer, SmartCella is accelerating its expansion plans and gearing up to enter the US market.
  • Nina Bauer says: "SmartCella was like a hidden gem to me, innovative and entrepreneurial in a very hot and fast developing research area.

IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease

Retrieved on: 
Dienstag, November 14, 2023
Swedish Research Council, Leukotriene, Safety, Nations in Swedish universities, Immunomodulation, Disease, PD, Cysteinyl leukotriene receptor 1, Tablet, Patient, Karolinska University Hospital, MPA, Alzheimer's disease, United, IGX, MD, SCI, Trial of the century, Neurodegenerative disease, Doctor of Philosophy, L-DOPA, TSX, Medical Products Agency (Sweden), Pharmaceutical industry

The current standard treatment of PD motor dysfunction is based on the enhancement of dopaminergic transmission and involves the administration of L-dopa.

Key Points: 
  • The current standard treatment of PD motor dysfunction is based on the enhancement of dopaminergic transmission and involves the administration of L-dopa.
  • Early results have indicated its potential usefulness for the treatment of various neurodegenerative disorders like PD and Alzheimer’s Disease.
  • The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm® or placebo twice daily for 18-months, followed by a 3-month washout period.
  • 3 Wallin, J; Svenningsson, P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease.

IntelGenx Reports Third Quarter 2023 Financial Results

Retrieved on: 
Donnerstag, November 9, 2023
Research, ANDA, Food, International, CDMO, Webcast, Stock, Investment, PD, Clinical trial, Depreciation, Karolinska University Hospital, Agency, IGX, Total, R, Doctor of Philosophy, TSX, Cryptocurrency, Bookkeeping, Video game, Pharmaceutical industry, Tilray, MD

SAINT LAURENT, Quebec, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • SAINT LAURENT, Quebec, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended September 30, 2023.
  • 2023 Third Quarter Financial Summary:
    Revenue was $318,000, compared to $142,000 in the 2022 third quarter.
  • “We received from Gensco® their first RIZAFILM® purchase order, which triggered an upfront payment and a milestone payment that are both reflected in our third quarter financial results.
  • IntelGenx will host a conference call to discuss these third quarter 2023 financial results today at 4:30 p.m.

Oncorena's first patient treated with ONC175 (orellanine) in clinical phase I/II trial in patients with metastatic renal cancer and dialysis at Karolinska University Hospital in Stockholm, Sweden

Retrieved on: 
Montag, September 4, 2023
Policy by press release, CSO, Pharmacokinetics, Medicine, Trial of the century, Dialysis, Karolinska University Hospital, Patient, Phase, Safety, Pharmaceutical industry

LUND, Sweden, Sept. 4, 2023 /PRNewswire/ -- Oncorena announces first patient treated in the Phase I/II trial of the first-in-class compound, ONC175 (orellanine), in patients with metastatic renal cancer and dialysis.

Key Points: 
  • LUND, Sweden, Sept. 4, 2023 /PRNewswire/ -- Oncorena announces first patient treated in the Phase I/II trial of the first-in-class compound, ONC175 (orellanine), in patients with metastatic renal cancer and dialysis.
  • The first treatment was conducted on August 8 without any complication at the Center for Clinical Cancer studies at Karolinska University Hospital, Stockholm, Sweden.
  • "I am happy to announce first patient, first treatment in our clinical phase I/II trial, Oncorella-1, with ONC175 (orellanine).
  • The clinical study, Oncorella-1, is conducted at the Center for Clinical Cancer Studies at Karolinska University Hospital, Stockholm, Sweden.

Oncorena's first patient treated with ONC175 (orellanine) in clinical phase I/II trial in patients with metastatic renal cancer and dialysis at Karolinska University Hospital in Stockholm, Sweden

Retrieved on: 
Montag, September 4, 2023
Policy by press release, CSO, Pharmacokinetics, Medicine, Trial of the century, Dialysis, Karolinska University Hospital, Patient, Phase, Safety, Pharmaceutical industry

LUND, Sweden, Sept. 4, 2023 /PRNewswire/ -- Oncorena announces first patient treated in the Phase I/II trial of the first-in-class compound, ONC175 (orellanine), in patients with metastatic renal cancer and dialysis.

Key Points: 
  • LUND, Sweden, Sept. 4, 2023 /PRNewswire/ -- Oncorena announces first patient treated in the Phase I/II trial of the first-in-class compound, ONC175 (orellanine), in patients with metastatic renal cancer and dialysis.
  • The first treatment was conducted on August 8 without any complication at the Center for Clinical Cancer studies at Karolinska University Hospital, Stockholm, Sweden.
  • "I am happy to announce first patient, first treatment in our clinical phase I/II trial, Oncorella-1, with ONC175 (orellanine).
  • The clinical study, Oncorella-1, is conducted at the Center for Clinical Cancer Studies at Karolinska University Hospital, Stockholm, Sweden.

XNK Therapeutics enters into research collaboration with Karolinska University Hospital in acute myeloid leukemia (AML)

Retrieved on: 
Donnerstag, August 24, 2023
Medicine, Central nervous system, University, Karolinska University Hospital, Infection, Acute leukemia, Bone marrow, NK, Research, MD Anderson Cancer Center, Cell, Haematopoietic system, Acute myeloid leukemia, AML, Patient, Anemia, Blood, Disease, Pharmaceutical industry

HUDDINGE, Sweden, Aug. 24, 2023 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that the company has entered into a research collaboration with the Karolinska University Hospital, Sweden, to evaluate the suitability of the company's autologous natural killer (NK) cell therapy candidate XNK02 as a novel therapy for treatment of acute myeloid leukemia (AML).

Key Points: 
  • HUDDINGE, Sweden, Aug. 24, 2023 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that the company has entered into a research collaboration with the Karolinska University Hospital, Sweden, to evaluate the suitability of the company's autologous natural killer (NK) cell therapy candidate XNK02 as a novel therapy for treatment of acute myeloid leukemia (AML).
  • In collaboration with Karolinska University Hospital, XNK will perform a large-scale bioreactor culture study of AML patients' immune cells.
  • "We look forward to conducting this important study together with the group of Dr Martin Jädersten, Medical lead for AML at the Karolinska University Hospital.
  • The research collaboration complements the current collaboration with the University of Texas MD Anderson Cancer Center to study XNK02 in AML patient material from various stages of the disease.

XNK Therapeutics enters into research collaboration with Karolinska University Hospital in acute myeloid leukemia (AML)

Retrieved on: 
Donnerstag, August 24, 2023
Medicine, Central nervous system, University, Karolinska University Hospital, Infection, Acute leukemia, Bone marrow, NK, Research, MD Anderson Cancer Center, Cell, Haematopoietic system, Acute myeloid leukemia, AML, Patient, Anemia, Blood, Disease, Pharmaceutical industry

HUDDINGE, Sweden, Aug. 24, 2023 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that the company has entered into a research collaboration with the Karolinska University Hospital, Sweden, to evaluate the suitability of the company's autologous natural killer (NK) cell therapy candidate XNK02 as a novel therapy for treatment of acute myeloid leukemia (AML).

Key Points: 
  • HUDDINGE, Sweden, Aug. 24, 2023 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that the company has entered into a research collaboration with the Karolinska University Hospital, Sweden, to evaluate the suitability of the company's autologous natural killer (NK) cell therapy candidate XNK02 as a novel therapy for treatment of acute myeloid leukemia (AML).
  • In collaboration with Karolinska University Hospital, XNK will perform a large-scale bioreactor culture study of AML patients' immune cells.
  • "We look forward to conducting this important study together with the group of Dr Martin Jädersten, Medical lead for AML at the Karolinska University Hospital.
  • The research collaboration complements the current collaboration with the University of Texas MD Anderson Cancer Center to study XNK02 in AML patient material from various stages of the disease.